atreleuton (A 85761) / AbbVie, VIA Pharma - LARVOL DELTA

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials. (PubMed, BMJ Open) - "These include (but are not limited to): non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, prednisone, methotrexate, canakinumab, pexelizumab, anakinra, succinobucol, losmapimod, inclacumab, atreleuton, LP-PLA (darapladib) and sPLA (varespladib). The findings will be disseminated through a peer-reviewed journal. CRD42022303289."

Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Immunology • Inflammation • Myocardial Infarction

Active Compounds in Zingiber officinale as Possible Redox Inhibitors of 5-Lipoxygenase Using an In Silico Approach. (PubMed, Int J Mol Sci) - "In the present study, 6-gingerol and 6-shogaol structures were analyzed and compared with two commercial 5-LOX inhibitors (zileuton and atreleuton) and with other inhibitor candidates (3f, NDGA, CP 209, caffeic acid, and caffeic acid phenethyl ester (CAPE)). These compounds could be inhibitors of 5-LOX because they present specific interactions with the residues involved in molecular inhibition. The current study demonstrated the potential of 6-gingerol and 6-shogaol as anti-inflammatory agents that inhibit 5-LOX, as they present a high level of performance in the toxicological analysis and could be catabolized by the cytochrome p450 enzymatic complex; however, 6-gingerol was superior in safety compared to 6-shogaol."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Anti-Inflammatory Therapeutics and Coronary Artery Disease. (PubMed, Cardiol Rev) - "This review will focus on several anti-inflammatories which have been studied in the context of cardiovascular disease- colchicine, canakinumab, VIA-2291, and methotrexate, and will highlight the potential benefits majority hold in hindering atherosclerosis and cardiovascular disease progression. This holds especially true for individuals already on optimal medical therapy who continue to be at high risk for adverse cardiovascular events."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Immunology • Inflammation

The role and transformative potential of IL-19 in atherosclerosis. (PubMed, Cytokine Growth Factor Rev) - "Most antiatherosclerotic drugs in current clinical use, including atorvastatin and alirocumab, target hyperlipidemia. Several other drugs have also been investigated in clinical trials as anti-inflammatory agents; the development of some of these agents has been terminated (canakinumab, darapladib, varespladib, losmapimod, atreleuton, setileuton, PF-04191834, veliflapon, and methotrexate), but others remain in development (ziltivekimab, tocilizumab, Somalix, IFM-2427, anakinra, mesenchymal stem cells (MSCs), colchicine, everolimus, allopurinol, and montelukast)...We propose that IL-19 is a promising biomarker and target for the diagnosis and treatment of atherosclerosis. This review considers the role and mechanism of action of IL-19 in atherosclerosis and discusses whether IL-19 is a potential therapeutic target for this condition."

Journal • Review • Atherosclerosis • Cardiovascular • CNS Disorders • Dyslipidemia • Immunology • Inflammation • Multiple Sclerosis • Orthopedics

5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach. (PubMed, Bioorg Med Chem) - "Currently, the only drug against 5-LOX which is available is Zileuton, while a few inhibitors are in clinical trial stages such as Atreleuton and Setileuton. So, there is a dire requirement in the area of progress of novel 5-LOX inhibitors which necessitates an understanding of their structure activity relationship and mode of action. In this review, novel 5-LOX inhibitors reported so far, their structural design, SAR and developmental strategies along with clinical updates are discussed over the last two decades."

Journal • Review • Allergy • Asthma • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Inflammation • Respiratory Diseases

Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome. (PubMed, J Cardiovasc Comput Tomogr) - P2 | "After adjustment for traditional cardiovascular risk factors including age, gender, body mass index, dyslipidemia and smoking, VIA-2291 decreases EAT and PAT in individuals with recent ACS. Treatment with the drug also appears to alter plaque volume and composition."

Clinical • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Immunology • Inflammation • Metabolic Disorders